Phase II Iressa + irradiation followed by chemo in NSCLC
Study identifier:1839IL/0530
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase II Open-Label Multicentre Study Of The Efficacy Of ZD1839 (IRESSA™) In Combination With Irradiation Followed By Chemotherapy In Patients With Inoperable Stage III Non Small Cell Lung Cancer
Medical condition
Non-small Cell Lung Cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
Gefitinib, Cisplatin, Vinorelbine
Sex
All
Actual Enrollment
50
Study type
Interventional
Age
18 Years - 75 Years
Date
Study Start Date: 01 Sept 2004
Primary Completion Date: -
Study Completion Date: 01 Jan 2006
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2007 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca France Medical Director
AstraZeneca
